Catalent Market Capitalization from 2010 to 2024
| CTLT Stock | USD 61.00 0.25 0.41% |
Check Catalent financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalent's main balance sheet or income statement drivers, such as Depreciation And Amortization of 513.5 M, Interest Expense of 158.6 M or Selling General Administrative of 577.9 M, as well as many indicators such as Price To Sales Ratio of 1.86, Dividend Yield of 2.0E-4 or PTB Ratio of 1.48. Catalent financial statements analysis is a perfect complement when working with Catalent Valuation or Volatility modules.
Catalent | Market Capitalization |
Latest Catalent's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Catalent over the last few years. It is Catalent's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalent's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 11.03 B | 10 Years Trend |
|
Market Cap |
| Timeline |
Catalent Market Capitalization Regression Statistics
| Arithmetic Mean | 7,242,752,291 | |
| Geometric Mean | 6,108,218,903 | |
| Coefficient Of Variation | 50.08 | |
| Mean Deviation | 3,108,914,747 | |
| Median | 7,891,696,253 | |
| Standard Deviation | 3,626,933,459 | |
| Sample Variance | 13154646.3T | |
| Range | 8.6B | |
| R-Value | 0.91 | |
| Mean Square Error | 2313235.9T | |
| R-Squared | 0.84 | |
| Slope | 741,843,703 | |
| Total Sum of Squares | 184165048.4T |
Catalent Market Capitalization History
About Catalent Financial Statements
Catalent shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although Catalent investors may analyze each financial statement separately, they are all interrelated. The changes in Catalent's assets and liabilities, for example, are also reflected in the revenues and expenses on on Catalent's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey. Catalent operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 19000 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.